Tahmid Rahman, MD

Multidisciplinary coordination and streamlined workflows enabled rapid patient access to plozasiran after FDA approval at Stony Brook University Hospital.

On Chen, MD; and Tahmid Rahman, MD, join Pharmacy Focus to discuss the world's first commercial administration of plozasiran at Stony Brook Medicine.

Multidisciplinary coordination and streamlined workflows enabled rapid patient access to plozasiran after FDA approval at Stony Brook University Hospital.

On Chen, MD, and Tahmid Rahman, MD, explain the real-world safety, dosing advantages, and pharmacist-driven identification strategies for patients who may benefit from plozasiran therapy.

Plozasiran offers a novel RNA-based mechanism to significantly reduce triglyceride levels in patients with familial chylomicronemia syndrome.